20 days ago
Ahead of the release of Zach Cregger's reboot today, there were already seven Resident Evil movies — six of them in a more action-oriented series starring Milla Jovovich, four of which were directed by her husband, Paul W.S. Anderson, plus an unrelated "reboot" in 2021 called Welcome to Raccoon City that went for more of a John Carpenter vibe and was an attempt to truly "adapt" the games. There's also a Netflix TV show version that ran for a single season in 2022. Countless other works in the horror genre have unofficially cribbed from the Resident Evil games over the years. It's an incredibly influential series.
And yet, Zach Cregger, hot off his Oscar-winning original horror film Weapons, is the first filmmaker to truly feel like he's adapting the experience of playing the games, arguably the scariest survival-horror ones ever made, rather than simply incorporating story and plot elements to explain the outbreak of infected people. In Cregger's hands, Resident Evil is pure crowd-pleasing popcorn cinema, best experienced in a packed movie theater with dozens of other people reacting loudly to the madness.
The premise couldn't be simpler — and the runtime a brisk 90ish minutes — as we follow a medical courier named Bryan (Austin Abrams, proving himself to be the Bruce Campbell for a new generation) who unwittingly finds himself fighting for survival as one fateful, horrifying night collapses around him in a swirl of chaos. Fans of the video games will recognize various easter eggs and nods to game mechanics, including the importance of conserving ammo and checking every last drawer for more of it.
But you don't need to be familiar with the games at all to enjoy the movie, which is an efficient horror set-piece machine that just keeps putting Abrams in increasingly concerning situations. I can't stress enough how much this is a one-man show anchored by Abrams, and he crushes it. He's in every scene, earning tons of laughs simply by reacting as a normal person would in this situation; he's a true audience-surrogate character, ushering us through the chaos. His comedic timing, paired with Cregger's ****** ured camerawork and editing, is a match made in genre-movie heaven.
I didn't expect it to be so heavily inspired by genre classics like The Thing and Evil Dead. In fact, it's a better Evil Dead movie than the last several movies with "Evil Dead" in the ****** le, nailing the horror-comedy tone that only Sam Raimi and a few others can pull off with aplomb. Cregger has a ton of fun with the various monstrous forms that the infected take here, from fusing multiple humans together to crafting his own horror take on a big, scary guy like Dune's Baron Harkonnen. Resident Evil movies have thus far treated the zombies as pretty traditional movie zombies; Cregger's version gets at the attempt to create the next stage of human evolution.
#resident #dead
And yet, Zach Cregger, hot off his Oscar-winning original horror film Weapons, is the first filmmaker to truly feel like he's adapting the experience of playing the games, arguably the scariest survival-horror ones ever made, rather than simply incorporating story and plot elements to explain the outbreak of infected people. In Cregger's hands, Resident Evil is pure crowd-pleasing popcorn cinema, best experienced in a packed movie theater with dozens of other people reacting loudly to the madness.
The premise couldn't be simpler — and the runtime a brisk 90ish minutes — as we follow a medical courier named Bryan (Austin Abrams, proving himself to be the Bruce Campbell for a new generation) who unwittingly finds himself fighting for survival as one fateful, horrifying night collapses around him in a swirl of chaos. Fans of the video games will recognize various easter eggs and nods to game mechanics, including the importance of conserving ammo and checking every last drawer for more of it.
But you don't need to be familiar with the games at all to enjoy the movie, which is an efficient horror set-piece machine that just keeps putting Abrams in increasingly concerning situations. I can't stress enough how much this is a one-man show anchored by Abrams, and he crushes it. He's in every scene, earning tons of laughs simply by reacting as a normal person would in this situation; he's a true audience-surrogate character, ushering us through the chaos. His comedic timing, paired with Cregger's ****** ured camerawork and editing, is a match made in genre-movie heaven.
I didn't expect it to be so heavily inspired by genre classics like The Thing and Evil Dead. In fact, it's a better Evil Dead movie than the last several movies with "Evil Dead" in the ****** le, nailing the horror-comedy tone that only Sam Raimi and a few others can pull off with aplomb. Cregger has a ton of fun with the various monstrous forms that the infected take here, from fusing multiple humans together to crafting his own horror take on a big, scary guy like Dune's Baron Harkonnen. Resident Evil movies have thus far treated the zombies as pretty traditional movie zombies; Cregger's version gets at the attempt to create the next stage of human evolution.
#resident #dead
23 days ago
Merck (MRK) was at the center of a major cancer-treatment update in August. Specifically, the drugmaker and Moderna (MRNA) said their personalized mRNA cancer therapy, intismeran autogene, delivered positive results in a Phase 3 study involving 1,137 patients with high-risk melanoma.
Used with Keytruda, the treatment reduced the risk of cancer returning or causing death and improved distant metastasis-free survival compared with Keytruda alone. Merck shares jumped 11% on the news. That was a big move for the stock, which had posted only five single-day gains of more than 5% over the past year.
This High-Yield Construction Stock Just Raised Its Dividend by 40%
Dear Intuit Stock Fans, Mark Your Calendars for September 17
This Dividend Stock Is Staging a Turnaround in 2026 and Pays More Than 2.4%
#Dividend #high #treatment #risk
Used with Keytruda, the treatment reduced the risk of cancer returning or causing death and improved distant metastasis-free survival compared with Keytruda alone. Merck shares jumped 11% on the news. That was a big move for the stock, which had posted only five single-day gains of more than 5% over the past year.
This High-Yield Construction Stock Just Raised Its Dividend by 40%
Dear Intuit Stock Fans, Mark Your Calendars for September 17
This Dividend Stock Is Staging a Turnaround in 2026 and Pays More Than 2.4%
#Dividend #high #treatment #risk
24 days ago
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#stage #survival
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ****** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#stage #survival
24 days ago
White House chief of staff Susie Wiles is "cancer free," she announced on X on Sept. 16, 2026. "Some personal news I'm grateful to share. After a medical appointment at the Mayo Clinic this week, my pathology results came back clear," she explained.
Wiles was diagnosed with early-stage breast cancer in March and told the New York Times that her prognosis was "strong." Wiles did not disclose at the time what treatment she would undergo, but said it would last several weeks — during which time she planned to continue working. Noting that one in eight American women develops breast cancer at some point in their lives, Wiles posted on X at the time: "Every day, these women continue to raise their families, go to work and serve their communities with strength and determination. I now join their ranks."
A breast cancer diagnosis is life-altering, but Wiles's comments highlighted the progress that's been made in recent years. Breast cancer is now detected at Stage 0 or 1 — before it has spread — in the majority of cases. Survival rates have risen dramatically, but "the treatments we use to treat early-stage breast cancer have become more tailored" and less disruptive to women's lives, Dr. Lynn Dengel, a University of Virginia surgical oncologist, told Yahoo in March.
"Because [Wiles] was taking care of her health [and getting screened], not only will her prognosis be better, but it will probably minimize what treatment she has to go through and will benefit her work-life and overall balance," Dengel said. She added that most of her patients are diagnosed early and can continue to work while undergoing breast cancer treatment, reducing the financial burden and overall disruption to their lives.
Wiles was diagnosed at age 68 — slightly older than the median age (62) when most women learn they have breast cancer. More than 380,000 American women are diagnosed with some form of breast cancer each year, according to the American Cancer Society (ACS).
Breast cancer remains the most common form of cancer among women in the U.S., except for skin cancers. And rates are rising. But there's good news: More women are surviving the disease. Treatments have also improved, becoming tolerable enough that many women still work, as Wiles intends to do. Here's what to know about the disease, why rates are rising and how women can reduce their risks.
#breast #diagnosed
Wiles was diagnosed with early-stage breast cancer in March and told the New York Times that her prognosis was "strong." Wiles did not disclose at the time what treatment she would undergo, but said it would last several weeks — during which time she planned to continue working. Noting that one in eight American women develops breast cancer at some point in their lives, Wiles posted on X at the time: "Every day, these women continue to raise their families, go to work and serve their communities with strength and determination. I now join their ranks."
A breast cancer diagnosis is life-altering, but Wiles's comments highlighted the progress that's been made in recent years. Breast cancer is now detected at Stage 0 or 1 — before it has spread — in the majority of cases. Survival rates have risen dramatically, but "the treatments we use to treat early-stage breast cancer have become more tailored" and less disruptive to women's lives, Dr. Lynn Dengel, a University of Virginia surgical oncologist, told Yahoo in March.
"Because [Wiles] was taking care of her health [and getting screened], not only will her prognosis be better, but it will probably minimize what treatment she has to go through and will benefit her work-life and overall balance," Dengel said. She added that most of her patients are diagnosed early and can continue to work while undergoing breast cancer treatment, reducing the financial burden and overall disruption to their lives.
Wiles was diagnosed at age 68 — slightly older than the median age (62) when most women learn they have breast cancer. More than 380,000 American women are diagnosed with some form of breast cancer each year, according to the American Cancer Society (ACS).
Breast cancer remains the most common form of cancer among women in the U.S., except for skin cancers. And rates are rising. But there's good news: More women are surviving the disease. Treatments have also improved, becoming tolerable enough that many women still work, as Wiles intends to do. Here's what to know about the disease, why rates are rising and how women can reduce their risks.
#breast #diagnosed
24 days ago
BioNTech SE (NASDAQ:BNTX) reported that its investigational lung-cancer drug gotistobart produced a clinically meaningful overall-survival benefit in the Phase 3 PRESERVE-003 trial in patients with metastatic squamous non-small cell lung cancer whose disease had progressed after prior immunotherapy and chemotherapy. Reuters said gotistobart nearly doubled survival compared with standard-of-care chemotherapy, strengthening the case for the drug as a potential chemotherapy-free treatment in a population with significant unmet need.
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#biontech #survival
The result builds on earlier Stage 1 data, where gotistobart reduced the risk of death by 54% versus docetaxel, with a hazard ratio of 0.46. Median overall survival was not yet reached for gotistobart versus 9.95 months for docetaxel, while the 12-month progression-free survival rate was 25.2% versus 0%. BioNTech is now awaiting the pivotal Stage 2 readout, making the latest result important not only for the drug's approval prospects but also for the credibility of BioNTech's broader transition from a COVID-vaccine company toward a multi-product oncology business.
The strongest bullish argument is that gotistobart now has repeated evidence of a meaningful survival advantage in a difficult-to-treat lung-cancer population. The earlier Stage 1 dataset showed 55.6% of patients alive in the gotistobart arm versus 23.8% with docetaxel, alongside a 54% reduction in the risk of death. The latest Phase 3 update reinforces that signal rather than introducing an entirely new hypothesis. If the pivotal Stage 2 data confirm the benefit, BioNTech SE (NASDAQ:BNTX) could have a differentiated therapy capable of competing on survival rather than simply response rates, potentially supporting meaningful pricing power and a commercially attractive oncology franchise.
The result also strengthens BioNTech's broader oncology strategy because gotistobart is one piece of a much larger pipeline rather than a standalone bet. BioNTech says it has 14 ongoing pivotal trials and more than 10 novel combination programs, while its lung-cancer strategy spans more than 16 ongoing clinical trials and five Phase 3 programs. Gotistobart's success therefore provides validation for the company's immuno-oncology capabilities, while other ***** ets such as pumitamig and antibody-drug conjugates advance toward additional indications. BioNTech has identified 17+ late-stage or pivotal readouts through 2030+, creating the possibility that a successful gotistobart launch becomes the first major commercial proof point in its planned transition to a multi-product oncology company.
#biontech #survival
26 days ago
Tom Sandoval became a household name because of Vanderpump Rules, but these days, he has gained the most attention for his very public split from his ex, Victoria Lee Robinson. Now, a recent report claims that the TV star has put his romance on ice after dumping his girlfriend.
According to TMZ, the 43-year-old actor was recently interviewed outside a pre-Emmy party in Los Angeles. During the conversation, Tom Sandoval said that his current focus is reconnecting with the people closest to him.
During the interview, the interviewer asked Sandoval about his dating plans and whether he planned to date anyone. However, he did not give a direct answer and instead named some of his friends with whom the TV personality has been spending time.
Tom also teased what he is preparing to do next, including his music, a Netflix survival show, and whether he would ever consider joining The Valley, a reality show.
Tom Sandoval and Victoria Lee Robinson had been friends for quite some time before they began dating in 2023. In 2024, the ex-couple publicly confirmed their relationship on Instagram. Reports suggest that in October 2024, the 34-year-old model moved in with the Vanderpump Rules star along with her father and four cats. At the time, Victoria Lee Robinson and her father reportedly had no jobs, so Sandoval covered all the household expenses.
#sandoval #Victoria
According to TMZ, the 43-year-old actor was recently interviewed outside a pre-Emmy party in Los Angeles. During the conversation, Tom Sandoval said that his current focus is reconnecting with the people closest to him.
During the interview, the interviewer asked Sandoval about his dating plans and whether he planned to date anyone. However, he did not give a direct answer and instead named some of his friends with whom the TV personality has been spending time.
Tom also teased what he is preparing to do next, including his music, a Netflix survival show, and whether he would ever consider joining The Valley, a reality show.
Tom Sandoval and Victoria Lee Robinson had been friends for quite some time before they began dating in 2023. In 2024, the ex-couple publicly confirmed their relationship on Instagram. Reports suggest that in October 2024, the 34-year-old model moved in with the Vanderpump Rules star along with her father and four cats. At the time, Victoria Lee Robinson and her father reportedly had no jobs, so Sandoval covered all the household expenses.
#sandoval #Victoria
28 days ago
Exelixis (EXEL) stock dropped out of a buy zone Friday after the Food and Drug Administration delayed the potential approval of its new colon cancer treatment by three months. The combination includes Exelixis' zanzalintinib and Roche's (RHHBY) Tecentriq. William Blair ***** yst Andy Hsieh says it's unlikely the agency will outright reject the combo, which showed an overall survival benefit for…
#rhhby #tecentriq #william
#rhhby #tecentriq #william
29 days ago
On September 3, AbbVie Inc. (NYSE:ABBV) finalized its acquisition of clinical-stage biotech Apogee Therapeutics, Inc. (NASDAQ:APGE) for $135.11 per share in cash. The $10.9 billion buyouts immediately fold Apogee's promising inflammatory and immunology (I&I) pipeline into AbbVie's commercial engine. On the exact same day, AbbVie separately reported positive Phase 3 Cervino trial results for its bispecific T-cell engager, etentamig, in relapsed/refractory multiple myeloma. Together, the dual catalysts emphasize how mega-cap pharmaceutical giants are deploying cash flow from legacy franchises to lock in next-generation immunology and oncology ***** ets.
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.
#phase #revenue #Growth
In Q2 2026, AbbVie Inc. (NYSE:ABBV) posted $16.99 billion in net revenue, up 10.2% year over year, while adjusted diluted EPS increased 22.9% to $3.65. Growth was driven by its immunology blockbusters, Skyrizi and Rinvoq, which generated $5.505 billion and $2.525 billion in revenue, respectively, representing growth of 24.4% and 24.5%. These gains more than offset the continued decline in Humira revenue, which fell 35.9% to $756 million amid biosimilar competition. AbbVie reiterated its full-year 2026 adjusted EPS guidance of $13.87–$14.07, including a $0.14 dilutive impact from the Apogee transaction.
As a clinical-stage biotech, Apogee Therapeutics, Inc. (NASDAQ:APGE) generated no product revenue in Q2 2026, while R&D expenses reached $67.3 million and G&A expenses totaled $24.3 million, resulting in a quarterly net loss of $85.9 million. Despite the cash burn, the company maintained a strong liquidity position, with $1.3 billion in cash and marketable securities, alongside a $1.3 billion non-dilutive credit collaboration with Blackstone Life Sciences to support Phase 3 trials of its lead ***** et, zumilokibart.
Financially, AbbVie is vastly superior in immediate cash generation and profitability, whereas Apogee represented pure clinical optionality backed by robust liquidity.
For AbbVie, acquiring Apogee's optimized antibody portfolio, including zumilokibart for atopic dermatitis, strengthens its post-Humira immunology franchise. Combined with internal R&D advances such as etentamig, which achieved statistically significant overall response rate and progression-free survival results in the Phase 3 Cervino study, along with an 87.9% 12-month overall survival rate, AbbVie demonstrates potential to sustain strong organic growth.
#phase #revenue #Growth
1 month ago
Fabio Grosso's dismissal by Fiorentina raises further questions over Paolo Maldini's shortlist for the Italy head coach position, with the former Viola boss previously considered alongside Andrea Pirlo and Daniele De Rossi.
Fiorentina parted ways with Grosso after he oversaw three consecutive Serie A defeats, bringing Paolo Vanoli back just three months after his departure.
FLORENCE, ITALY – SEPTEMBER 5: Head coach Fabio Grosso manager of ACF Fiorentina looks on during the Serie A match between ACF Fiorentina and Torino FC at Stadio Artemio Franchi on September 5, 2026 in Florence, Italy. (Photo by Gabriele Maltinti/Getty Images)
Grosso completed his first full Serie A season as a coach in 2025-26, leading Sassuolo to a comfortable survival and convincing Fabio Paratici to give him a chance at the Stadio Franchi.
Regarded as one of the most exciting young coaches in Serie A, Grosso had also caught the attention of ex-Italy technical director Maldini, who retained his role for just two weeks in July.
#italy #coach #paolo #florence
Fiorentina parted ways with Grosso after he oversaw three consecutive Serie A defeats, bringing Paolo Vanoli back just three months after his departure.
FLORENCE, ITALY – SEPTEMBER 5: Head coach Fabio Grosso manager of ACF Fiorentina looks on during the Serie A match between ACF Fiorentina and Torino FC at Stadio Artemio Franchi on September 5, 2026 in Florence, Italy. (Photo by Gabriele Maltinti/Getty Images)
Grosso completed his first full Serie A season as a coach in 2025-26, leading Sassuolo to a comfortable survival and convincing Fabio Paratici to give him a chance at the Stadio Franchi.
Regarded as one of the most exciting young coaches in Serie A, Grosso had also caught the attention of ex-Italy technical director Maldini, who retained his role for just two weeks in July.
#italy #coach #paolo #florence
1 month ago
Roberto De Zerbi's Tottenham Hotspur were held to a goalless draw by Nottingham Forest on Saturday afternoon, as the Italian coach's 'revolution' in North London struggles to gather pace.
De Zerbi guided the club to Premier League survival after taking over late last season and helped engineer an expensive squad overhaul in the summer transfer window, with over €200m spent on midfielders alone.
However, Spurs remain winless and are now without a goal in their opening three league matches for the first time since 1974. Pressure is already beginning to mount on the former Sassuolo and Brighton boss to quickly find solutions to his side's mounting offensive woes, despite the vast amounts of money spent to supposedly improve it.
SYDNEY, AUSTRALIA – AUGUST 01: Italy international Sandro Tonali of Tottenham Hotspur celebrates scoring a goal during the Sydney Super Cup match between Chelsea FC and Tottenham at Accor Stadium on August 01, 2026 in Sydney, Australia. (Photo by Brendon Thorne/Getty Images)
Both Sandro Tonali and Destiny Udogie started for De Zerbi at the City Ground today. Tonali, who completed a marquee move from Newcastle United earlier in the summer, put in a full ninety-minute shift and stood out as one of Spurs' few bright spots, dictating play from the base of the midfield.
#zerbi
De Zerbi guided the club to Premier League survival after taking over late last season and helped engineer an expensive squad overhaul in the summer transfer window, with over €200m spent on midfielders alone.
However, Spurs remain winless and are now without a goal in their opening three league matches for the first time since 1974. Pressure is already beginning to mount on the former Sassuolo and Brighton boss to quickly find solutions to his side's mounting offensive woes, despite the vast amounts of money spent to supposedly improve it.
SYDNEY, AUSTRALIA – AUGUST 01: Italy international Sandro Tonali of Tottenham Hotspur celebrates scoring a goal during the Sydney Super Cup match between Chelsea FC and Tottenham at Accor Stadium on August 01, 2026 in Sydney, Australia. (Photo by Brendon Thorne/Getty Images)
Both Sandro Tonali and Destiny Udogie started for De Zerbi at the City Ground today. Tonali, who completed a marquee move from Newcastle United earlier in the summer, put in a full ninety-minute shift and stood out as one of Spurs' few bright spots, dictating play from the base of the midfield.
#zerbi
1 month ago
Population is the most seductive number in business. It looks like a customer list before anyone has spent a dollar.
For most of the past 15 years, that logic decided where American technology companies planted flags. Find the countries with the most people and the youngest median age, arrive early, and wait for incomes to catch up to the app.
The playbook worked in India. It worked in Brazil. It turned Southeast Asia into a decade-long trench war between well-funded rivals.
Nigeria was supposed to be next in that sequence. It has more people than Russia and ****** an combined, a median age under 20, and in Lagos, a commercial capital where traffic is bad enough that paying for a ride is less of a luxury than a survival tax.
I have watched that thesis get pasted into investor decks for a decade, usually with a map and an arrow. This week it ran into an income statement, and the income statement won.
#income #american
For most of the past 15 years, that logic decided where American technology companies planted flags. Find the countries with the most people and the youngest median age, arrive early, and wait for incomes to catch up to the app.
The playbook worked in India. It worked in Brazil. It turned Southeast Asia into a decade-long trench war between well-funded rivals.
Nigeria was supposed to be next in that sequence. It has more people than Russia and ****** an combined, a median age under 20, and in Lagos, a commercial capital where traffic is bad enough that paying for a ride is less of a luxury than a survival tax.
I have watched that thesis get pasted into investor decks for a decade, usually with a map and an arrow. This week it ran into an income statement, and the income statement won.
#income #american
1 month ago
Revolution Medicines, Inc. (NASDAQ:RVMD) received FDA approval for Rasonque, or daraxonrasib, following an expedited review. The once-daily oral RAS inhibitor is approved for adults with metastatic pancreatic adenocarcinoma who have received at least one prior systemic therapy or are not candidates for multiagent systemic therapy.
Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) of $39,800 for a 30-day supply. Twelve 30-day supplies would total $477,600 at WAC before discounts, rebates, or ******* istance. Rasonque is available in the United States, with (ON)Path offering insurance navigation and financial-assistance resources, including copay support for eligible commercially insured patients.
The approval was based on RASolute 302, a randomized Phase 3 trial involving 500 patients with previously treated metastatic pancreatic adenocarcinoma. In the overall population, median overall survival reached 13.2 months with Rasonque versus 6.7 months with chemotherapy. The hazard ratio of 0.40 represented a 60% lower hazard of death during trial follow-up. Median progression-free survival was 7.2 months versus 3.6 months, while objective response rates were 30% and 11%, respectively.
The survival benefit gives Rasonque a strong clinical argument for reimbursement. Pancreatic cancer is aggressive, treatment options after progression are limited, and Rasonque improved overall survival, progression-free survival, and response rates in a randomized comparison. Oral dosing may also reduce the burden of intravenous chemotherapy.
The approved population is broader than a single mutation-defined subgroup. Rasonque can be prescribed with or without an identified RAS tumor mutation and does not require a companion diagnostic. That reduces testing friction within the approved treatment setting.
#months #pancreatic #progression #medicines
Revolution Medicines, Inc. (NASDAQ:RVMD) set a wholesale acquisition cost (WAC) of $39,800 for a 30-day supply. Twelve 30-day supplies would total $477,600 at WAC before discounts, rebates, or ******* istance. Rasonque is available in the United States, with (ON)Path offering insurance navigation and financial-assistance resources, including copay support for eligible commercially insured patients.
The approval was based on RASolute 302, a randomized Phase 3 trial involving 500 patients with previously treated metastatic pancreatic adenocarcinoma. In the overall population, median overall survival reached 13.2 months with Rasonque versus 6.7 months with chemotherapy. The hazard ratio of 0.40 represented a 60% lower hazard of death during trial follow-up. Median progression-free survival was 7.2 months versus 3.6 months, while objective response rates were 30% and 11%, respectively.
The survival benefit gives Rasonque a strong clinical argument for reimbursement. Pancreatic cancer is aggressive, treatment options after progression are limited, and Rasonque improved overall survival, progression-free survival, and response rates in a randomized comparison. Oral dosing may also reduce the burden of intravenous chemotherapy.
The approved population is broader than a single mutation-defined subgroup. Rasonque can be prescribed with or without an identified RAS tumor mutation and does not require a companion diagnostic. That reduces testing friction within the approved treatment setting.
#months #pancreatic #progression #medicines
1 month ago
After a year marked by controversy, cancellations and mounting questions about its future, LIV Golf's final event at The Club at Chatham Hills in Indianapolis saw 22-year-old Michael La Sasso capture what could prove to be the final event in the league's tenure.
Of course, that remains speculation for now. Reports and rumors regarding the league's long-term survival continue to circulate, but no official announcement has been made regarding LIV's future. What is no longer in question, however, is that the circuit faces a series of significant headwinds.
More: This LIV Golf star was DQ'd in his DP World Tour qualifying attempt
Financial concerns have become increasingly difficult to ignore. The league has spent much of the year navigating a changing business landscape while exploring ways to reinvent itself for the future. Plans for a leaner, restructured version of the circuit have been discussed, but uncertainty remains about how and when such a model could take shape.
But after the biggest victory of his life, La Sasso and four fellow LIV players are taking steps to secure another pathway in professional golf, entering the DP World Tour's Qualifying School in hopes of earning status on Europe's top tour.
#year #golf #tour #qualifying
Of course, that remains speculation for now. Reports and rumors regarding the league's long-term survival continue to circulate, but no official announcement has been made regarding LIV's future. What is no longer in question, however, is that the circuit faces a series of significant headwinds.
More: This LIV Golf star was DQ'd in his DP World Tour qualifying attempt
Financial concerns have become increasingly difficult to ignore. The league has spent much of the year navigating a changing business landscape while exploring ways to reinvent itself for the future. Plans for a leaner, restructured version of the circuit have been discussed, but uncertainty remains about how and when such a model could take shape.
But after the biggest victory of his life, La Sasso and four fellow LIV players are taking steps to secure another pathway in professional golf, entering the DP World Tour's Qualifying School in hopes of earning status on Europe's top tour.
#year #golf #tour #qualifying
1 month ago
Can-Fite BioPharma Ltd. (NYSE:CANF) reported extended survival trends in a key late-stage cancer trial alongside a $4 million warrant exercise agreement to fund ongoing clinical operations.
• Can Fite Biopharma stock is at significant support. What is going on with CANF?
The clinical-stage biotechnology company observed longer-than-expected blinded overall survival in its ongoing pivotal Phase 3 trial evaluating Namodenoson for advanced hepatocellular carcinoma (HCC).
The study focuses on HCC patients with Child-Pugh B7 cirrhosis, utilizing overall survival as its primary efficacy endpoint.
Because the observed data reflect a pooled, blinded population across both treatment arms, the company cannot draw conclusions regarding drug efficacy or comparative differences yet.
#biopharma #clinical
• Can Fite Biopharma stock is at significant support. What is going on with CANF?
The clinical-stage biotechnology company observed longer-than-expected blinded overall survival in its ongoing pivotal Phase 3 trial evaluating Namodenoson for advanced hepatocellular carcinoma (HCC).
The study focuses on HCC patients with Child-Pugh B7 cirrhosis, utilizing overall survival as its primary efficacy endpoint.
Because the observed data reflect a pooled, blinded population across both treatment arms, the company cannot draw conclusions regarding drug efficacy or comparative differences yet.
#biopharma #clinical
1 month ago
Concerned about an AI bubble? Sign up for The Daily Upside for smart and actionable market news, built for investors.
A cancer diagnosis is never something anyone is ready for, but when it happens, the effects can go well beyond the physical and emotional traumas that turn lives upside down.
There are financial aspects that, if not addressed, can affect quality of life and even survival rates. Having a financial planner in their corner can help patients organize, ensure they're getting the most from their benefits and prepare as much as possible for whatever comes next. "With cancer, you get diagnosed, and then there is this few-week window before they start treatment," said Dr. Carolyn McClanahan, a physician and financial planner. That's a critical time for putting a plan in place, as "once you start treatment, it can be a drain on your physical and mental health."
The National Cancer Institute has a term for devastating financial consequences resulting from the high costs of medical care patients and their families face: financial toxicity. While it's inherently financial in nature, the stress it causes has real medical implications. That makes financial planning incredibly important, especially for those struggling with the high costs of care:
A pilot study of 107 patients being treated for blood cancers found that comprehensive planning resulted in higher mental and physical quality of life, among those experiencing financial toxicity.
#physical #start
A cancer diagnosis is never something anyone is ready for, but when it happens, the effects can go well beyond the physical and emotional traumas that turn lives upside down.
There are financial aspects that, if not addressed, can affect quality of life and even survival rates. Having a financial planner in their corner can help patients organize, ensure they're getting the most from their benefits and prepare as much as possible for whatever comes next. "With cancer, you get diagnosed, and then there is this few-week window before they start treatment," said Dr. Carolyn McClanahan, a physician and financial planner. That's a critical time for putting a plan in place, as "once you start treatment, it can be a drain on your physical and mental health."
The National Cancer Institute has a term for devastating financial consequences resulting from the high costs of medical care patients and their families face: financial toxicity. While it's inherently financial in nature, the stress it causes has real medical implications. That makes financial planning incredibly important, especially for those struggling with the high costs of care:
A pilot study of 107 patients being treated for blood cancers found that comprehensive planning resulted in higher mental and physical quality of life, among those experiencing financial toxicity.
#physical #start
1 month ago
Jose Mourinho has settled on his insurance policy for the season, and it is not about star power. Rather, it is about survival.
According to a report from Defensa Central, the Real Madrid manager has identified a specific group of players, namely, Eduardo Camavinga, Alvaro Carreras, Brahim Diaz and new arrival Yan Diomande, as the players he intends to lean on to keep his squad fresh and competitive across a demanding 2026/27 campaign.
As per the outlet, this is supposed to be a direct response to a problem that has haunted Real Madrid for the best part of two seasons.
It must be remembered that Real Madrid have recorded more than a hundred injuries since 2024, a run of fitness setbacks that has disrupted team continuity and forced coaches into reactive squad management.
Mourinho, by contrast, appears intent on getting ahead of it.
#according
According to a report from Defensa Central, the Real Madrid manager has identified a specific group of players, namely, Eduardo Camavinga, Alvaro Carreras, Brahim Diaz and new arrival Yan Diomande, as the players he intends to lean on to keep his squad fresh and competitive across a demanding 2026/27 campaign.
As per the outlet, this is supposed to be a direct response to a problem that has haunted Real Madrid for the best part of two seasons.
It must be remembered that Real Madrid have recorded more than a hundred injuries since 2024, a run of fitness setbacks that has disrupted team continuity and forced coaches into reactive squad management.
Mourinho, by contrast, appears intent on getting ahead of it.
#according
1 month ago
The Bundesliga is back! On Matchday 1, Freiburg host Werder Bremen in an exciting opening fixture for both sides. Goalkeeper Mio Backhaus (and potentially Eren **** çi as well) will face his former club, adding an extra layer of intrigue to the matchup.
Julian Schuster's side will be looking to improve on last season and push for a return to the European places, with a Europa League spot potentially within reach. Bremen, meanwhile, have one primary objective: survival. After a shaky 2025/26 campaign that saw them finish 15th, Werder will be hoping to take a step forward this season - with Niclas Füllkrug expected to play a key role in their ambitions.
Who will come out on top in this match? With just about an hour to go until kickoff, here are the confirmed lineups for both sides:
SC Freiburg (4-2-3-1): Backhaus - Kübler, Ginter, Lienhart, Makengo - Eggestein, Engelhardt - Beste, Suzuki, Scherhant - Matanović
Werder Bremen (4-3-3): Hein - Schmetgens, Pieper, Friedl, Deman - Chuky, Reis, Lynen - Njinmah, Füllkrug, Grüll
#werder #freiburg #sides
Julian Schuster's side will be looking to improve on last season and push for a return to the European places, with a Europa League spot potentially within reach. Bremen, meanwhile, have one primary objective: survival. After a shaky 2025/26 campaign that saw them finish 15th, Werder will be hoping to take a step forward this season - with Niclas Füllkrug expected to play a key role in their ambitions.
Who will come out on top in this match? With just about an hour to go until kickoff, here are the confirmed lineups for both sides:
SC Freiburg (4-2-3-1): Backhaus - Kübler, Ginter, Lienhart, Makengo - Eggestein, Engelhardt - Beste, Suzuki, Scherhant - Matanović
Werder Bremen (4-3-3): Hein - Schmetgens, Pieper, Friedl, Deman - Chuky, Reis, Lynen - Njinmah, Füllkrug, Grüll
#werder #freiburg #sides
1 month ago
Revolution Medicines, Inc. (NASDAQ:RVMD) touched an all-time high above $224 on August 27, 2026, following FDA approval of Rasonque (daraxonrasib) – the first broad RAS-targeted therapy cleared for metastatic pancreatic cancer. Creating a milestone, the approval came roughly five weeks after filing under the agency's national priority voucher. The pivotal RASolute 302 trial nearly doubled median overall survival, to 13.2 months from 6.7 on chemotherapy. While the clinical benefit is substantial, a $47 billion valuation suggests the market had already priced in this success.
RVMD carries essentially no product revenue yet. Its price rests entirely on the future. Evercore ISI has raised the next-year sales estimate for Rasonque to ~$2.4 billion. Additionally, the $47 billion valuation discounts much of a long-term pancreatic opportunity which the Evercore **** yst estimates Rasonque could generate about $15.1 billion in pancreatic-cancer sales by 2034. However, a few details complicate this math. First, the approved label applies strictly to second-line or multiagent-ineligible patients. The front-line indication represents the larger market opportunity but remains pending, meaning a notable portion of the TAM is not yet accessible. Second, RVMD's current valuation also sits well above the $28 billion–$32 billion takeover valuation reportedly discussed with Merck earlier this year. Bulls argue lung and colorectal trials justify the $47 billion beyond pancreatic cancer, though that pipeline potential remains unproven.
That matters because Revolution Medicines must now execute its first commercial launch independently in one of oncology's most challenging indications characterized by short survival, high patient frailty, and a U.S. list price of $39,800 for a 30-day supply. Commercialization will require heavy spending. The second-quarter net loss widened to $644 million, and full-year operating expense guidance increased to between $2.1 and $2.2 billion. While a $3.9 billion cash balance and up to $1.5 billion in committed royalty financing fund the launch, operational execution remains the primary risk.
Insiders were net sellers of roughly $21.5 million over the past 90 days with zero buying. Hedge fund data on the stock is flat. As per the Insider Monkey database, 105 funds held RVMD in the second quarter of 2026, modestly down from 106 in the first, indicating strong conviction among institutional investors. Short interest sits near 6% of float, representing a modest level of bets against the stock.
#first
RVMD carries essentially no product revenue yet. Its price rests entirely on the future. Evercore ISI has raised the next-year sales estimate for Rasonque to ~$2.4 billion. Additionally, the $47 billion valuation discounts much of a long-term pancreatic opportunity which the Evercore **** yst estimates Rasonque could generate about $15.1 billion in pancreatic-cancer sales by 2034. However, a few details complicate this math. First, the approved label applies strictly to second-line or multiagent-ineligible patients. The front-line indication represents the larger market opportunity but remains pending, meaning a notable portion of the TAM is not yet accessible. Second, RVMD's current valuation also sits well above the $28 billion–$32 billion takeover valuation reportedly discussed with Merck earlier this year. Bulls argue lung and colorectal trials justify the $47 billion beyond pancreatic cancer, though that pipeline potential remains unproven.
That matters because Revolution Medicines must now execute its first commercial launch independently in one of oncology's most challenging indications characterized by short survival, high patient frailty, and a U.S. list price of $39,800 for a 30-day supply. Commercialization will require heavy spending. The second-quarter net loss widened to $644 million, and full-year operating expense guidance increased to between $2.1 and $2.2 billion. While a $3.9 billion cash balance and up to $1.5 billion in committed royalty financing fund the launch, operational execution remains the primary risk.
Insiders were net sellers of roughly $21.5 million over the past 90 days with zero buying. Hedge fund data on the stock is flat. As per the Insider Monkey database, 105 funds held RVMD in the second quarter of 2026, modestly down from 106 in the first, indicating strong conviction among institutional investors. Short interest sits near 6% of float, representing a modest level of bets against the stock.
#first
1 month ago
Tempus AI, Inc. (NASDAQ:TEM) rallied following a melanoma breakthrough reported by Moderna and Merck. The companies said their Phase 3 INTerpath-001 trial met its recurrence-free survival endpoint for the personalized cancer therapy intismeran autogene, also known as V940, combined with Keytruda. Detailed trial data remain pending. The read-through came from Personalis, which has supported the V940 clinical-development program since its inception. Tempus agreed in July to a pending acquisition of Personalis at a $1.5 billion enterprise value, net of Tempus's existing stake. The question for Tempus AI, Inc. (NASDAQ:TEM) is whether the result validates the acquisition or merely confirms that one Personalis platform is strategically relevant to personalized cancer therapy.
Personalis uses ImmunoID NeXT to sequence tumor information for personalized vaccine development. That technology is distinct from NeXT Personal, the company's tumor-informed molecular residual disease test and the central strategic target of the acquisition. For Tempus AI, Inc. (NASDAQ:TEM), the clinical result validates Personalis's sequencing capabilities without establishing the economics of either product.
Tempus AI, Inc. (NASDAQ:TEM) is acquiring a company that has supported the V940 program from its beginning. A successful Phase 3 endpoint could strengthen Personalis's credibility with biopharma customers and create additional sequencing opportunities as drugmakers pursue individualized therapies across more tumor types.
The acquisition also reaches beyond vaccine sequencing. Tempus AI, Inc. (NASDAQ:TEM) has commercialized NeXT Personal since 2023. The MRD test searches for small traces of circulating tumor DNA after treatment, helping clinicians monitor response and identify possible recurrence before it becomes visible through conventional imaging.
Tempus AI, Inc. (NASDAQ:TEM) reported 9,000 total MRD tests in the second quarter, up from 6,500 sequentially. Personalis generated finalized quarterly revenue of $22.357 million and delivered 10,384 clinical tests, with volume rising 33% sequentially. NeXT Personal also has Medicare coverage in three indications, giving the pending transaction a commercial foundation independent of V940.
#v940 #acquisition #tumor
Personalis uses ImmunoID NeXT to sequence tumor information for personalized vaccine development. That technology is distinct from NeXT Personal, the company's tumor-informed molecular residual disease test and the central strategic target of the acquisition. For Tempus AI, Inc. (NASDAQ:TEM), the clinical result validates Personalis's sequencing capabilities without establishing the economics of either product.
Tempus AI, Inc. (NASDAQ:TEM) is acquiring a company that has supported the V940 program from its beginning. A successful Phase 3 endpoint could strengthen Personalis's credibility with biopharma customers and create additional sequencing opportunities as drugmakers pursue individualized therapies across more tumor types.
The acquisition also reaches beyond vaccine sequencing. Tempus AI, Inc. (NASDAQ:TEM) has commercialized NeXT Personal since 2023. The MRD test searches for small traces of circulating tumor DNA after treatment, helping clinicians monitor response and identify possible recurrence before it becomes visible through conventional imaging.
Tempus AI, Inc. (NASDAQ:TEM) reported 9,000 total MRD tests in the second quarter, up from 6,500 sequentially. Personalis generated finalized quarterly revenue of $22.357 million and delivered 10,384 clinical tests, with volume rising 33% sequentially. NeXT Personal also has Medicare coverage in three indications, giving the pending transaction a commercial foundation independent of V940.
#v940 #acquisition #tumor
1 month ago
BioNTech SE (NASDAQ:BNTX) rallied following the first positive interim Phase 3 topline result for a personalized mRNA cancer therapy. Moderna and Merck said intismeran, combined with Keytruda, significantly improved recurrence-free and distant metastasis-free survival in patients with surgically removed high-risk melanoma. The result lifted other mRNA developers because it provided the strongest evidence yet that the technology can work against cancer in a large late-stage trial. For BioNTech SE (NASDAQ:BNTX), however, the rally raises a harder question: does validation of the therapeutic class meaningfully improve the odds for its own candidates, or has the market moved ahead of company-specific evidence?
The distinction matters. Moderna's intismeran is individually designed around mutations found in each patient's tumor. BioNTech SE (NASDAQ:BNTX) is awaiting an interim ******* ysis from the Phase 3 portion of AHEAD-MERIT, which tests BNT113 with pembrolizumab in first-line unresectable recurrent or metastatic HPV16-positive, PD-L1-positive head-and-neck squamous cell carcinoma. BNT113 is an off-the-shelf FixVac therapy encoding the HPV16 E6 and E7 oncoproteins. Different antigens, manufacturing approaches, cancer types and treatment settings prevent Moderna's result from functioning as a direct clinical read-through.
Still, BioNTech SE (NASDAQ:BNTX) has more than one attempt at building an oncology franchise. The company has 14 ongoing pivotal trials across mRNA immunotherapies, immunomodulators and antibody-drug conjugates. It expects three late-stage readouts during 2026, including the BNT113 interim ******* ysis, and ended June with €16.6 billion in cash, cash equivalents and security investments.
The bull case for BioNTech SE (NASDAQ:BNTX) is that Moderna and Merck have reduced skepticism around the broader platform. Their trial enrolled 1,137 patients and met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival, with no new safety concerns reported. The result shows that an mRNA therapy can add meaningful benefit to a checkpoint inhibitor in Phase 3.
BioNTech also has a personalized program that more closely resembles intismeran. Autogene cevumeran, partnered with Genentech, is being studied in randomized Phase 2 trials in pancreatic and colorectal cancer. Meanwhile, BNT113 has FDA Fast Track designation and could provide BioNTech's own pivotal mRNA evidence. The company's cash position gives it room to fund these programs and absorb failures elsewhere in the portfolio.
#biontech
The distinction matters. Moderna's intismeran is individually designed around mutations found in each patient's tumor. BioNTech SE (NASDAQ:BNTX) is awaiting an interim ******* ysis from the Phase 3 portion of AHEAD-MERIT, which tests BNT113 with pembrolizumab in first-line unresectable recurrent or metastatic HPV16-positive, PD-L1-positive head-and-neck squamous cell carcinoma. BNT113 is an off-the-shelf FixVac therapy encoding the HPV16 E6 and E7 oncoproteins. Different antigens, manufacturing approaches, cancer types and treatment settings prevent Moderna's result from functioning as a direct clinical read-through.
Still, BioNTech SE (NASDAQ:BNTX) has more than one attempt at building an oncology franchise. The company has 14 ongoing pivotal trials across mRNA immunotherapies, immunomodulators and antibody-drug conjugates. It expects three late-stage readouts during 2026, including the BNT113 interim ******* ysis, and ended June with €16.6 billion in cash, cash equivalents and security investments.
The bull case for BioNTech SE (NASDAQ:BNTX) is that Moderna and Merck have reduced skepticism around the broader platform. Their trial enrolled 1,137 patients and met its primary endpoint of recurrence-free survival and a secondary endpoint of distant metastasis-free survival, with no new safety concerns reported. The result shows that an mRNA therapy can add meaningful benefit to a checkpoint inhibitor in Phase 3.
BioNTech also has a personalized program that more closely resembles intismeran. Autogene cevumeran, partnered with Genentech, is being studied in randomized Phase 2 trials in pancreatic and colorectal cancer. Meanwhile, BNT113 has FDA Fast Track designation and could provide BioNTech's own pivotal mRNA evidence. The company's cash position gives it room to fund these programs and absorb failures elsewhere in the portfolio.
#biontech
1 month ago
Aug 28 (Reuters) - BioNTech SE said on Friday it has decided to terminate the mid-stage trial of its experimental mRNA-based cancer vaccine for patients with a type of colorectal cancer, sending the German firm's U.S.-listed shares down nearly 9%.
An independent data safety monitoring board, responsible for overseeing the safety and integrity of the trial, recommended discontinuing treatment of patients and terminating the study.
The immunotherapy, autogene cevumeran, is being jointly developed by BioNTech and Roche's Genentech. The trial was evaluating it as an adjuvant monotherapy in patients with high-risk stage II or stage III colorectal cancer whose tumors had been surgically removed but who remained ctDNA-positive.
In its most recent review of the available data of this trial, the board identified a numerical imbalance in overall survival between treatment arms in this specific patient population and noted that further trial continuation was unlikely to change the efficacy outcome.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
#patients #colorectal
An independent data safety monitoring board, responsible for overseeing the safety and integrity of the trial, recommended discontinuing treatment of patients and terminating the study.
The immunotherapy, autogene cevumeran, is being jointly developed by BioNTech and Roche's Genentech. The trial was evaluating it as an adjuvant monotherapy in patients with high-risk stage II or stage III colorectal cancer whose tumors had been surgically removed but who remained ctDNA-positive.
In its most recent review of the available data of this trial, the board identified a numerical imbalance in overall survival between treatment arms in this specific patient population and noted that further trial continuation was unlikely to change the efficacy outcome.
(Reporting by Sriparna Roy in Bengaluru; Editing by Shilpi Majumdar)
#patients #colorectal
1 month ago
On August 13, Celcuity (NASDAQ:CELC) walked investors through a quarter unlike any in the company's history. The clinical-stage biotech is no longer just clinical: its breast cancer drug Revtopik won FDA approval on July 14, and the call was built around how the company plans to turn that approval into an actual business. The tone was confident, but the numbers underneath told a more complicated story about what launching a first drug really costs.
The regulatory news alone stood out. The FDA approved Revtopik on July 14 for patients with HR positive, HER2-negative advanced breast cancer without a PIK3CA mutation who had progressed on prior endocrine therapy. Less than three weeks later, the National Comprehensive Cancer Network recommended both the Revtopik triplet and doublet as preferred Category 1 options for second-line treatment, a fast endorsement suggesting oncologists see real value here.
That value shows up in the data. In the PIK3CA mutant cohort of the VIKTORIA-1 trial, the gedatolisib triplet produced a median progression-free survival of 11.1 months versus 5.6 months for alpelisib plus fulvestrant, cutting the risk of progression or death in half. Just 5.2% of triplet patients and 3.8% of doublet patients stopped treatment due to side effects, compared to 19% on alpelisib. CEO Sullivan said that 4% to 5% range "best represents what we expect to see in a real world setting," a detail that matters because patients who stay on a drug longer generate more revenue over time.
Celcuity is not stopping at second-line treatment either. The VIKTORIA-2 trial has been expanded to test gedatolisib in treatment-naive, endocrine-sensitive patients, a group that makes up roughly two-thirds of newly diagnosed advanced breast cancer cases each year. That bet is backed by earlier Phase 1b data showing a median progression-free survival of 48.6 months, nearly double the roughly 25 months typical of current standard of care. Commercially, the company says its 80-person oncology sales team, averaging 24 years of experience, is fully built, backed by $754 million in cash management expects to last into 2029.
Turning that approval into revenue has been expensive. Net loss widened to $78.9 million, or $1.44 per share, for the quarter, compared to a loss of $45.3 million a year earlier. Selling, general, and administrative expenses jumped $27.4 million to $35 million, driven mostly by hiring the commercial team needed to support the launch. Celcuity has not shipped a single vial yet, with shipments not expected to begin until late in the third quarter of 2026.
#cancer #months #quarter
The regulatory news alone stood out. The FDA approved Revtopik on July 14 for patients with HR positive, HER2-negative advanced breast cancer without a PIK3CA mutation who had progressed on prior endocrine therapy. Less than three weeks later, the National Comprehensive Cancer Network recommended both the Revtopik triplet and doublet as preferred Category 1 options for second-line treatment, a fast endorsement suggesting oncologists see real value here.
That value shows up in the data. In the PIK3CA mutant cohort of the VIKTORIA-1 trial, the gedatolisib triplet produced a median progression-free survival of 11.1 months versus 5.6 months for alpelisib plus fulvestrant, cutting the risk of progression or death in half. Just 5.2% of triplet patients and 3.8% of doublet patients stopped treatment due to side effects, compared to 19% on alpelisib. CEO Sullivan said that 4% to 5% range "best represents what we expect to see in a real world setting," a detail that matters because patients who stay on a drug longer generate more revenue over time.
Celcuity is not stopping at second-line treatment either. The VIKTORIA-2 trial has been expanded to test gedatolisib in treatment-naive, endocrine-sensitive patients, a group that makes up roughly two-thirds of newly diagnosed advanced breast cancer cases each year. That bet is backed by earlier Phase 1b data showing a median progression-free survival of 48.6 months, nearly double the roughly 25 months typical of current standard of care. Commercially, the company says its 80-person oncology sales team, averaging 24 years of experience, is fully built, backed by $754 million in cash management expects to last into 2029.
Turning that approval into revenue has been expensive. Net loss widened to $78.9 million, or $1.44 per share, for the quarter, compared to a loss of $45.3 million a year earlier. Selling, general, and administrative expenses jumped $27.4 million to $35 million, driven mostly by hiring the commercial team needed to support the launch. Celcuity has not shipped a single vial yet, with shipments not expected to begin until late in the third quarter of 2026.
#cancer #months #quarter
1 month ago
NEW DELHI: Anaya Bangar has responded to criticism from South Africa all-rounder Marizanne Kapp over her bid to return to competitive women's cricket, urging those opposed to her participation to "educate themselves" on the subject.
Kapp had strongly criticised Cricket Australia's decision to offer Anaya a pathway back into competitive women's cricket, calling it "absolutely ridiculous" and saying "this should not be allowed".
The comments came after Cricket Australia cleared Anaya, daughter of former India cricketer and coach Sanjay Bangar, for a pathway towards elite women's cricket under its Inclusion of Transgender and Gender Diverse Players in Elite Cricket Policy.
Anaya, who underwent gender-affirming surgery in March this year, is currently eligible to play community cricket in any state or territory of Australia. Her eligibility for elite cricket from March 2027 remains subject to the policy requirements.
Anaya's potential return has generated reactions on both sides, with the 25-year-old now responding directly to Kapp's criticism.
"I think people who want to raise their voice against it should actually educate themselves on this topic, and I've already provided the necessary information in terms of not having any unfair advantage, and also complying with the guidelines set by Cricket Australia.
"If anyone's personal opinion is in that sort of way, I hope they go and educate themselves," she said with a shrug while speaking to PTI.
Anaya is hoping to eventually pursue a pathway to the Women's Big Bash League, although she is yet to sign up with a local club. Her immediate focus is on playing at the community level and proving herself through her performances.
Anaya said she had spent a long period in "survival mode" and was only now beginning to process everything she had experienced during her transition and the long road back to cricket.
"...basically now, the next role is to go there and play club cricket and prove myself by my performances, and if I do well, I hopefully might have a chance to be picked for the Women's Big Bash League. So, baby steps from here, but the major part of having a place to play has been cleared," she said.
She is currently in talks with a few cricket clubs and is waiting to decide on the right one "to go there and start playing."
For Anaya, the CA decision represents a significant breakthrough after years away from competitive cricket. While she has been given a pathway, it does not guarantee selection in any team.
Anaya further added that the process was neither "automatic or informal", with CA considering her medical and surgical history, hormone and testosterone levels, cricketing background, playing footage and scientific and athletic performance work undertaken with Manchester Metropolitan University's Institute of Sport.
She also said her most recent blood test in July recorded total testosterone at 0.6 nanomoles, which she said was within the female reference rang
Kapp had strongly criticised Cricket Australia's decision to offer Anaya a pathway back into competitive women's cricket, calling it "absolutely ridiculous" and saying "this should not be allowed".
The comments came after Cricket Australia cleared Anaya, daughter of former India cricketer and coach Sanjay Bangar, for a pathway towards elite women's cricket under its Inclusion of Transgender and Gender Diverse Players in Elite Cricket Policy.
Anaya, who underwent gender-affirming surgery in March this year, is currently eligible to play community cricket in any state or territory of Australia. Her eligibility for elite cricket from March 2027 remains subject to the policy requirements.
Anaya's potential return has generated reactions on both sides, with the 25-year-old now responding directly to Kapp's criticism.
"I think people who want to raise their voice against it should actually educate themselves on this topic, and I've already provided the necessary information in terms of not having any unfair advantage, and also complying with the guidelines set by Cricket Australia.
"If anyone's personal opinion is in that sort of way, I hope they go and educate themselves," she said with a shrug while speaking to PTI.
Anaya is hoping to eventually pursue a pathway to the Women's Big Bash League, although she is yet to sign up with a local club. Her immediate focus is on playing at the community level and proving herself through her performances.
Anaya said she had spent a long period in "survival mode" and was only now beginning to process everything she had experienced during her transition and the long road back to cricket.
"...basically now, the next role is to go there and play club cricket and prove myself by my performances, and if I do well, I hopefully might have a chance to be picked for the Women's Big Bash League. So, baby steps from here, but the major part of having a place to play has been cleared," she said.
She is currently in talks with a few cricket clubs and is waiting to decide on the right one "to go there and start playing."
For Anaya, the CA decision represents a significant breakthrough after years away from competitive cricket. While she has been given a pathway, it does not guarantee selection in any team.
Anaya further added that the process was neither "automatic or informal", with CA considering her medical and surgical history, hormone and testosterone levels, cricketing background, playing footage and scientific and athletic performance work undertaken with Manchester Metropolitan University's Institute of Sport.
She also said her most recent blood test in July recorded total testosterone at 0.6 nanomoles, which she said was within the female reference rang
1 month ago
Paderborn return to the German top-flight this season following their promotion play-off victory over Wolfsburg. The club return to the Bundesliga for the first time since relegation following the 2019/20 season, having finished 18th.
Paderborn previously had two spells in the Bundesliga, in 2014/15 and 2019/20, being relegated both times after just one season.
Survival will be their main goal, but just how likely is that?
They will face Mainz in their opener at the MEWA Arena on Saturday, August 29.
Paderborn had a reasonably impressive preseason. After thrashing the amateur Blau-Weiß Ostenland 18-0, they went on to get some decent results, losing only one match (2-0 against Magdeburg).
#bundesliga
Paderborn previously had two spells in the Bundesliga, in 2014/15 and 2019/20, being relegated both times after just one season.
Survival will be their main goal, but just how likely is that?
They will face Mainz in their opener at the MEWA Arena on Saturday, August 29.
Paderborn had a reasonably impressive preseason. After thrashing the amateur Blau-Weiß Ostenland 18-0, they went on to get some decent results, losing only one match (2-0 against Magdeburg).
#bundesliga
1 month ago
Merck & Co., Inc. (NYSE:MRK) jumped 12.6% to a record $152.20 on August 19 after a pivotal melanoma trial validated intismeran autogene, the individualized mRNA cancer therapy developed with Moderna. In the 1,137-patient Phase 3 INTerpath-001 study, intismeran plus Keytruda produced statistically significant and clinically meaningful improvements in recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone. No new safety concerns emerged. Investors are now asking whether intismeran can turn Keytruda from a drug approaching a patent cliff into the foundation of a personalized-cancer platform.
That distinction matters because Merck & Co., Inc. (NYSE:MRK) generated $31.68 billion from Keytruda and Keytruda Qlex in 2025, nearly half of the company's sales. In the U.S., biosimilar competition could begin after Keytruda's primary compound patent expires in December 2028, although biosimilars have already entered some smaller international markets. A successful combination could support continued use of the franchise without removing the need for other growth engines.
The bullish case for Merck & Co., Inc. (NYSE:MRK) is that intismeran adds a personalized immune response to a checkpoint inhibitor already embedded across oncology. The treatment is designed from the unique mutations in each patient's tumor and encodes as many as 34 neoantigens, training the immune system to recognize tumor cells while Keytruda removes a brake on the immune response.
Earlier Phase 2b data showed a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death at five years. Phase 3 confirmation makes the approach more credible for Merck & Co., Inc. (NYSE:MRK) beyond melanoma. The company is also studying intismeran combinations in non-small cell lung, bladder and renal-cell cancers. Success across several tumor types could create a portfolio of Keytruda combinations rather than a single indication.
That would give Merck & Co., Inc. (NYSE:MRK) another lifecycle-management tool alongside Keytruda Qlex and newer oncology ***** ets. It also strengthens the argument that Keytruda can remain commercially relevant after standalone pembrolizumab faces lower-priced competition.
#NYSE #tumor #cancer
That distinction matters because Merck & Co., Inc. (NYSE:MRK) generated $31.68 billion from Keytruda and Keytruda Qlex in 2025, nearly half of the company's sales. In the U.S., biosimilar competition could begin after Keytruda's primary compound patent expires in December 2028, although biosimilars have already entered some smaller international markets. A successful combination could support continued use of the franchise without removing the need for other growth engines.
The bullish case for Merck & Co., Inc. (NYSE:MRK) is that intismeran adds a personalized immune response to a checkpoint inhibitor already embedded across oncology. The treatment is designed from the unique mutations in each patient's tumor and encodes as many as 34 neoantigens, training the immune system to recognize tumor cells while Keytruda removes a brake on the immune response.
Earlier Phase 2b data showed a 49% reduction in the risk of recurrence or death and a 59% reduction in distant metastasis or death at five years. Phase 3 confirmation makes the approach more credible for Merck & Co., Inc. (NYSE:MRK) beyond melanoma. The company is also studying intismeran combinations in non-small cell lung, bladder and renal-cell cancers. Success across several tumor types could create a portfolio of Keytruda combinations rather than a single indication.
That would give Merck & Co., Inc. (NYSE:MRK) another lifecycle-management tool alongside Keytruda Qlex and newer oncology ***** ets. It also strengthens the argument that Keytruda can remain commercially relevant after standalone pembrolizumab faces lower-priced competition.
#NYSE #tumor #cancer
2 months ago
Over-the-counter anti-aging supplements taken by millions of Americans to boost energy and lessen the side effects of chemotherapy may actually impair cancer treatments, a new study suggests.
Researchers at the Case Western Reserve University School of Medicine found that popular vitamin B3 derivatives – including nicotinamide mononucleotide (NMN), nicotinamide riboside (NR) and nicotinamide (NAM) – could help cancer cells survive chemotherapy.
Those compounds are used by the body to produce NAD+, a molecule that helps cells generate energy and repair damage.
Iv Therapy And Supplements Under Scrutiny As Experts Warn Of Potential Side Effects
The study, published in the journal Cancer Letters, examined how these supplements interact with treatments for pancreatic cancer, a particularly deadly form of the disease with a 13% five-year survival rate, according to the American Cancer Society.
#nicotinamide #energy #chemotherapy
Researchers at the Case Western Reserve University School of Medicine found that popular vitamin B3 derivatives – including nicotinamide mononucleotide (NMN), nicotinamide riboside (NR) and nicotinamide (NAM) – could help cancer cells survive chemotherapy.
Those compounds are used by the body to produce NAD+, a molecule that helps cells generate energy and repair damage.
Iv Therapy And Supplements Under Scrutiny As Experts Warn Of Potential Side Effects
The study, published in the journal Cancer Letters, examined how these supplements interact with treatments for pancreatic cancer, a particularly deadly form of the disease with a 13% five-year survival rate, according to the American Cancer Society.
#nicotinamide #energy #chemotherapy
2 months ago
It's an elimination day at the Little League World Series and South Korea and Canada are playing for survival in the tournament. The two teams meet again with everything at stake. South Korea dominated the first meeting 7-0 and looked unstoppable before a heartbreaking 1-0 loss to Curaçao.
Canada refused to quit, earning wins over Australia and Panama to stay alive. Now the rematch has arrived.
Will Canada get revenge or will South Korea move one step closer to the International Championship? Williamsport is ready for one of Tuesday's must-watch games.
Watch LLWS games with Fubo
All times Eastern and accurate as of Monday, Aug. 24, 2026, at 4:02 p.m.
#south #korea #games #little
Canada refused to quit, earning wins over Australia and Panama to stay alive. Now the rematch has arrived.
Will Canada get revenge or will South Korea move one step closer to the International Championship? Williamsport is ready for one of Tuesday's must-watch games.
Watch LLWS games with Fubo
All times Eastern and accurate as of Monday, Aug. 24, 2026, at 4:02 p.m.
#south #korea #games #little
2 months ago
The department store model isn't dying. Instead, it is quietly reshaping itself. While headlines typically highlight massive retail contractions, including Macy's closing 80 stores and Saks Global's Chapter 11 bankruptcy, some of the legacy chains are executing strategic footprint adjustments instead of a full retreat.
Few retailers illustrate this survival shift better than Nordstrom. The legacy luxury retailer's story is doubly challenging as it is not only a department store chain, but a mall retailer as well. As such it has to deal with the following trials:
The shrinking mall: Projections from Capital One Shopping suggest up to 87% of traditional shopping malls could close over the next decade.
Digital competition: IBISWorld data highlights accelerating market share loss from department stores to e-commerce rivals.
Cautious consumers: Shoppers are planning to further pull back spending across most discretionary categories, according to recent surveys from McKinsey & Company.
#legacy #mall #chapter #nordstrom
Few retailers illustrate this survival shift better than Nordstrom. The legacy luxury retailer's story is doubly challenging as it is not only a department store chain, but a mall retailer as well. As such it has to deal with the following trials:
The shrinking mall: Projections from Capital One Shopping suggest up to 87% of traditional shopping malls could close over the next decade.
Digital competition: IBISWorld data highlights accelerating market share loss from department stores to e-commerce rivals.
Cautious consumers: Shoppers are planning to further pull back spending across most discretionary categories, according to recent surveys from McKinsey & Company.
#legacy #mall #chapter #nordstrom
2 months ago
AstraZeneca PLC (NYSE:AZN) is paying $600 million upfront to secure global rights to Zegfrovy from Dizal Pharmaceutical Co., Ltd, adding another targeted therapy to one of the pharmaceutical industry's largest oncology portfolios. Dizal Pharmaceutical could receive an additional $900 million if specified development, regulatory, and sales milestones are achieved, bringing the agreement's potential value to $1.5 billion. Dizal will also receive tiered royalties on the global sales of Zegfrovy.
Zegfrovy, also known as sunvozertinib, is an oral treatment approved in the United States and China for certain adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Under the agreement, AstraZeneca (NYSE:AZN) will take responsibility for the treatment's global development and commercialisation.
For AstraZeneca (NYSE:AZN) shareholders, the transaction offers an opportunity to ****** s whether another targeted lung-cancer medicine can reinforce the company's oncology leadership, or whether the price adds further execution risk to an already extensive pipeline.
The agreement strengthens AstraZeneca's (NYSE:AZN) position in a therapeutic area where it already has substantial scientific and commercial experience. The company has built a major lung-cancer business around treatments including Tagrisso, Imfinzi, and Enhertu. That existing infrastructure could help AstraZeneca (NYSE:AZN) introduce Zegfrovy to physicians and patients more efficiently than a smaller developer with a limited global presence.
Zegfrovy also addresses a specific group of patients with EGFR exon 20 insertion mutations, for whom treatment options remain limited. In the Phase III WU-KONG28 trial, Zegfrovy produced median progression-free survival of 10.3 months, compared with 7.5 months for chemotherapy. AstraZeneca (NYSE:AZN) therefore gains an approved medicine supported by late-stage comparative evidence rather than an early experimental ****** et whose clinical viability remains largely unknown.
#lung #egfr
Zegfrovy, also known as sunvozertinib, is an oral treatment approved in the United States and China for certain adults with locally advanced or metastatic non-small cell lung cancer with EGFR exon 20 insertion mutations, whose disease has progressed on or after platinum-based chemotherapy. Under the agreement, AstraZeneca (NYSE:AZN) will take responsibility for the treatment's global development and commercialisation.
For AstraZeneca (NYSE:AZN) shareholders, the transaction offers an opportunity to ****** s whether another targeted lung-cancer medicine can reinforce the company's oncology leadership, or whether the price adds further execution risk to an already extensive pipeline.
The agreement strengthens AstraZeneca's (NYSE:AZN) position in a therapeutic area where it already has substantial scientific and commercial experience. The company has built a major lung-cancer business around treatments including Tagrisso, Imfinzi, and Enhertu. That existing infrastructure could help AstraZeneca (NYSE:AZN) introduce Zegfrovy to physicians and patients more efficiently than a smaller developer with a limited global presence.
Zegfrovy also addresses a specific group of patients with EGFR exon 20 insertion mutations, for whom treatment options remain limited. In the Phase III WU-KONG28 trial, Zegfrovy produced median progression-free survival of 10.3 months, compared with 7.5 months for chemotherapy. AstraZeneca (NYSE:AZN) therefore gains an approved medicine supported by late-stage comparative evidence rather than an early experimental ****** et whose clinical viability remains largely unknown.
#lung #egfr
2 months ago
A drug used to treat erectile dysfunction and enlarged prostate symptoms may raise the risk of glaucoma, a serious eye condition that can cause gradual vision loss, according to new research.
An international team of researchers ****** yzed health records from nearly 74,000 men ages 40 and older with lower urinary tract symptoms to examine whether long-term tadalafil use was ****** ociated with a greater risk of glaucoma.
The study, published in the British Journal of Ophthalmology, compared about 37,000 men prescribed tadalafil with a similar group who did not use phosphodiesterase type 5 inhibitors, the drug class that includes Cialis.
Researchers followed the men for up to five years and looked for new cases of glaucoma and high pressure inside the eye, along with whether patients needed treatment for glaucoma.
Vision Problem Leads To Man's Stage 4 Lung Cancer Diagnosis, New Drug Extends Survival
#drug #researchers #risk
An international team of researchers ****** yzed health records from nearly 74,000 men ages 40 and older with lower urinary tract symptoms to examine whether long-term tadalafil use was ****** ociated with a greater risk of glaucoma.
The study, published in the British Journal of Ophthalmology, compared about 37,000 men prescribed tadalafil with a similar group who did not use phosphodiesterase type 5 inhibitors, the drug class that includes Cialis.
Researchers followed the men for up to five years and looked for new cases of glaucoma and high pressure inside the eye, along with whether patients needed treatment for glaucoma.
Vision Problem Leads To Man's Stage 4 Lung Cancer Diagnosis, New Drug Extends Survival
#drug #researchers #risk
